MOESM2 of Impact of transfusion on patients with sepsis admitted in intensive care unit: a systematic review and meta-analysis

Additional file 2: Additional Tables and Figures

MOESM1 of Impact of transfusion on patients with sepsis admitted in intensive care unit: a systematic review and meta-analysis

Additional file 1: Search strategy, Boolean algorithms an definition used into the study

Acute kidney injury and renal replacement therapy in patients with severe sepsis or septic shock: comparison of all cases (with diabetes) and controls (without diabetes).

<p>Acute kidney injury and renal replacement therapy in patients with severe sepsis or septic shock: comparison of all cases (with diabetes) and controls (without diabetes).</p

Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival

<div><h3>Background</h3><p>Optimal chemotherapy with minimal toxicity is the main determinant of complete remission in patients with newly diagnosed hematological malignancies. Acute organ dysfunctions may impair the patient’s ability to receive optimal chemotherapy.</p> <h3>Design and Methods</h3><p>To compare 6-month complete remission rates in patients with and without acute kidney injury (AKI), we collected prospective data on 200 patients with newly diagnosed high-grade malignancies (non-Hodgkin lymphoma, 53.5%; acute myeloid leukemia, 29%; acute lymphoblastic leukemia, 11.5%; and Hodgkin disease, 6%).</p> <h3>Results</h3><p>According to RIFLE criteria, 137 (68.5%) patients had AKI. Five causes of AKI accounted for 91.4% of cases: hypoperfusion, tumor lysis syndrome, tubular necrosis, nephrotoxic agents, and hemophagocytic lymphohistiocytosis. Half of the AKI patients received renal replacement therapy and 14.6% received suboptimal chemotherapy. AKI was associated with a lower 6-month complete remission rate (39.4% vs. 68.3%, <em>P</em><0.01) and a higher mortality rate (47.4% vs. 30.2%, <em>P</em><0.01) than patients without AKI. By multivariate analysis, independent determinants of 6-month complete remission were older age, poor performance status, number of organ dysfunctions, and AKI.</p> <h3>Conclusion</h3><p>AKI is common in patients with newly diagnosed high-grade malignancies and is associated with lower complete remission rates and higher mortality.</p> </div

Characteristics of acute kidney injury (n = 137).

<p>ICU, intensive care unit; AKI, acute kidney injury; RRT, renal replacement therapy.</p

Baseline characteristics of patients with severe sepsis or septic shock with (cases) or without (controls) diabetes mellitus.

<p>Baseline characteristics of patients with severe sepsis or septic shock with (cases) or without (controls) diabetes mellitus.</p

Outcome data.

<p>IQR, interquartile range; AKI, acute kidney injury.</p

6-month outcome probabilities in patients with newly diagnosed hematological malignancies.

<p>A three-state model was used: alive with hematological malignancy, alive in complete remission, and dead. All patients start in state alive with hematological malignancy. The black line represents the overall survival and the dashed line current survival free of malignancy, defined as the probability of being alive and in complete remission. Results are presented for the whole cohort and stratified according to the presence of AKI at day 1. AKI, acute kidney injury; ICU, intensive care unit.</p

Effects of RIFLE classification on complete remission at 6 months.

<p>RIFLE classification scheme for acute kidney injury (AKI). The classification system includes separate criteria for creatinine and urine output (UO). A patient can fulfill the criteria through changes in serum creatinine (SCreat) or changes in UO, or both within 7 days. The criteria that lead to the worst possible classification should be used. R, RIFLE risk category: increased SCreat×1.5 or Glomerular filtration Rate (GFR) decrease >25% or UO <0.5 ml/kg/h×6 hours. I, RIFLE injury category: increased SCreat×2 or GFR decrease >50% or UO <0.5 ml/kg/h×12 hours. F, RIFLE failure category: increased SCreat×3 or SCreat greater than 4.0 mg/dl (350 µmol/l) with an acute increase of at least 0.5 mg/dl (44 µmol/l) or GFR decrease >75% or UO <0.3 ml/kg/h×24 hours or anuria×12 hours.</p

Patient flow chart.

<p>Patient flow chart.</p